Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Oct 02 04:00PM ET
6.93
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-0.28 Insider Own3.71% Shs Outstand232.45M Perf Week14.17%
Market Cap1.63B Forward P/E- EPS next Y-0.07 Insider Trans-11.91% Shs Float226.68M Perf Month23.09%
Income-65.14M PEG- EPS next Q-0.05 Inst Own62.20% Short Float11.44% Perf Quarter30.26%
Sales210.00M P/S7.77 EPS this Y14.24% Inst Trans50.49% Short Ratio7.17 Perf Half Y-5.71%
Book/sh0.62 P/B11.10 EPS next Y71.28% ROA-23.49% Short Interest25.93M Perf Year70.69%
Cash/sh0.79 P/C8.77 EPS next 5Y30.00% ROE-48.23% 52W Range3.16 - 10.13 Perf YTD11.77%
Dividend Est.- P/FCF- EPS past 5Y28.61% ROI-26.23% 52W High-31.59% Beta0.89
Dividend TTM- Quick Ratio3.99 Sales past 5Y146.90% Gross Margin84.83% 52W Low119.30% ATR (14)0.34
Dividend Ex-Date- Current Ratio4.21 EPS Y/Y TTM4.76% Oper. Margin-28.05% RSI (14)67.50 Volatility6.76% 5.11%
Employees267 Debt/Eq0.71 Sales Y/Y TTM153.42% Profit Margin-31.02% Recom1.20 Target Price11.28
Option/ShortYes / Yes LT Debt/Eq0.69 EPS Q/Q11.81% Payout- Rel Volume0.00 Prev Close6.93
Sales Surprise33.06% EPS Surprise33.96% Sales Q/Q227.86% EarningsAug 01 AMC Avg Volume3.62M Price6.93
SMA2012.47% SMA5015.74% SMA200-2.34% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Jul-02-24Downgrade Piper Sandler Overweight → Neutral $15 → $7
Apr-05-24Initiated Leerink Partners Outperform $14
Dec-18-23Initiated Raymond James Strong Buy $12
Sep-07-23Initiated H.C. Wainwright Buy $9
Aug-25-23Upgrade Cantor Fitzgerald Neutral → Overweight $5 → $10
Mar-03-23Upgrade Wedbush Neutral → Outperform $3 → $6
Nov-17-22Upgrade Piper Sandler Neutral → Overweight $3 → $8
May-06-22Downgrade Cantor Fitzgerald Overweight → Neutral $7 → $1
Dec-01-21Upgrade Ladenburg Thalmann Neutral → Buy $6
Oct-14-21Downgrade Ladenburg Thalmann Buy → Neutral
Today 05:45AM
Sep-30-24 01:02PM
Sep-10-24 05:45AM
Sep-06-24 05:45AM
Sep-05-24 08:00AM
12:43PM Loading…
Aug-28-24 12:43PM
Aug-08-24 08:00AM
Aug-01-24 07:30PM
05:45PM
04:42PM
04:01PM
Jul-31-24 08:02AM
Jul-25-24 10:01AM
Jul-18-24 02:53PM
08:00AM
05:10PM Loading…
Jul-17-24 05:10PM
Jul-02-24 07:00AM
Jun-28-24 08:17AM
Jun-24-24 07:30AM
Jun-16-24 06:17AM
May-30-24 04:02PM
03:30PM
May-22-24 08:02AM
May-21-24 08:02AM
May-19-24 04:00PM
May-16-24 08:01AM
May-15-24 04:30PM
May-14-24 04:02PM
May-09-24 04:43PM
May-07-24 05:00PM
08:01AM Loading…
08:01AM
May-04-24 11:00AM
May-03-24 02:16PM
09:57AM
07:31AM
06:21AM
May-02-24 08:58PM
05:45PM
04:47PM
04:02PM
May-01-24 08:00AM
Apr-25-24 10:02AM
Apr-18-24 08:00AM
Apr-02-24 11:34AM
Mar-28-24 04:05PM
Mar-25-24 08:00AM
Mar-16-24 06:00PM
Mar-12-24 04:35PM
Feb-28-24 05:40PM
Feb-27-24 08:00AM
06:10AM
Feb-23-24 10:16AM
Feb-22-24 06:00PM
05:15PM
04:45PM
04:26PM
04:01PM
Feb-19-24 03:30PM
12:24PM
Feb-15-24 10:00AM
Feb-09-24 09:55AM
08:50AM
Feb-08-24 12:16PM
12:00PM
09:40AM
Feb-07-24 09:34AM
Feb-06-24 04:00PM
Feb-02-24 02:15AM
Feb-01-24 08:00AM
Jan-29-24 12:35PM
Jan-12-24 07:56AM
Jan-10-24 02:27PM
Jan-08-24 08:00AM
Jan-03-24 08:03AM
Dec-29-23 11:01PM
Dec-20-23 08:00AM
Dec-14-23 06:40AM
Dec-05-23 09:11AM
Nov-21-23 04:02PM
09:37AM
08:01AM
Nov-17-23 09:00AM
Nov-15-23 04:02PM
Nov-13-23 04:02PM
Nov-10-23 08:05AM
Nov-06-23 08:00AM
Nov-03-23 08:00AM
Nov-02-23 09:40AM
Nov-01-23 10:42AM
Oct-31-23 11:15PM
05:09PM
08:40AM
07:29AM
07:00AM
Oct-30-23 05:42PM
Oct-23-23 08:07AM
Oct-19-23 10:21AM
Oct-18-23 04:31PM
04:02PM
10:42AM
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rosenbaum David P.Chief Development OfficerSep 27 '24Sale6.9249,564342,983301,946Oct 01 04:34 PM
DAVID P ROSENBAUM OfficerSep 27 '24Proposed Sale6.3649,564315,227Sep 27 04:26 PM
RAAB MICHAELPresident & CEOSep 26 '24Sale6.073,00018,2101,217,608Sep 27 04:09 PM
MICHAEL G. RAABOfficerSep 26 '24Proposed Sale6.073,00018,210Sep 26 04:10 PM
Rosenbaum David P.Chief Development OfficerSep 13 '24Sale6.265,31233,254153,616Sep 16 06:14 PM
RAAB MICHAELPresident & CEOSep 11 '24Option Exercise0.9935,00034,6501,255,608Sep 13 04:35 PM
RAAB MICHAELPresident & CEOSep 11 '24Sale5.6135,000196,3991,220,608Sep 13 04:35 PM
MICHAEL G. RAABOfficerSep 11 '24Proposed Sale5.6135,000196,399Sep 11 04:08 PM
RAAB MICHAELPresident & CEOAug 27 '24Sale6.227,50046,6351,219,509Aug 28 05:45 PM
MICHAEL G. RAABOfficerAug 27 '24Proposed Sale6.227,50046,635Aug 27 04:09 PM
SUSAN RODRIGUEZ OfficerAug 26 '24Proposed Sale6.3772,612462,560Aug 26 04:49 PM
Williams Laura AChief Medical OfficerAug 20 '24Sale5.867,41243,437314,740Aug 22 06:28 PM
Rosenbaum David P.Chief Development OfficerAug 20 '24Sale5.864,96929,120351,510Aug 22 06:26 PM
Rosenbaum David P.Chief Development OfficerAug 20 '24Sale5.862,25013,186156,252Aug 22 06:26 PM
Renz Justin AChief Financial OfficerAug 20 '24Sale5.865,28930,995295,257Aug 22 06:25 PM
RAAB MICHAELPresident & CEOAug 20 '24Sale5.8632,225188,8481,227,009Aug 22 06:24 PM
GRAMMER ELIZABETH ASee RemarksAug 20 '24Sale5.867,08941,544192,380Aug 22 06:22 PM
Felsch Robert OraSee RemarksAug 20 '24Sale5.863,56720,90491,560Aug 22 06:21 PM
Blanks RobertSee RemarksAug 20 '24Sale5.864,96929,120319,362Aug 22 06:20 PM
Rosenbaum David P.Chief Development OfficerAug 20 '24Option Exercise0.9920,50720,302179,009Aug 20 06:59 PM
Rosenbaum David P.Chief Development OfficerAug 20 '24Sale6.0020,507123,042158,502Aug 20 06:59 PM
Rosenbaum David P.Chief Development OfficerAug 16 '24Sale5.9420,000118,740356,479Aug 20 06:59 PM
DAVID P ROSENBAUM TODSUBJECT TOfficerAug 16 '24Proposed Sale5.8820,000117,600Aug 16 04:28 PM
RAAB MICHAELPresident & CEOAug 12 '24Sale5.711,2297,0181,259,234Aug 14 06:16 PM
MICHAEL G. RAABOfficerAug 12 '24Proposed Sale5.711,2297,018Aug 12 04:35 PM
RAAB MICHAELPresident & CEOJul 29 '24Option Exercise0.9930,00029,7001,290,463Jul 31 07:54 PM
RAAB MICHAELPresident & CEOJul 29 '24Sale5.6430,000169,3141,260,463Jul 31 07:54 PM
MICHAEL G. RAABOfficerJul 29 '24Proposed Sale5.6430,000169,314Jul 29 04:41 PM
RAAB MICHAELPresident & CEOJul 15 '24Sale5.977,50044,7681,260,463Jul 17 05:54 PM
RAAB MICHAELPresident & CEOJun 28 '24Sale6.592,31015,2231,267,963Jun 28 05:37 PM
Blanks RobertSee RemarksJun 21 '24Sale5.9638,000226,290324,331Jun 25 06:22 PM
RAAB MICHAELPresident & CEOJun 13 '24Option Exercise0.9935,00034,6501,305,273Jun 17 06:46 PM
RAAB MICHAELPresident & CEOJun 13 '24Sale6.6535,000232,7431,270,273Jun 17 06:46 PM
Williams Laura AChief Medical OfficerJun 05 '24Option Exercise2.75100,000275,000467,152Jun 07 06:29 PM
Williams Laura AChief Medical OfficerJun 05 '24Sale7.12145,0001,033,080322,152Jun 07 06:29 PM
Rosenbaum David P.Chief Development OfficerJun 03 '24Sale7.0017,872125,104158,502Jun 05 08:00 PM
RAAB MICHAELPresident & CEOMay 29 '24Sale6.727,50050,3901,270,273May 31 04:31 PM
Williams Laura AChief Medical OfficerMay 21 '24Sale7.814,79437,446367,152May 23 04:21 PM
Rosenbaum David P.Chief Development OfficerMay 21 '24Sale7.814,85537,922376,479May 23 04:19 PM
Rosenbaum David P.Chief Development OfficerMay 21 '24Sale7.812,19817,169176,374May 23 04:19 PM
Rodriguez SusanChief Commercial OfficerMay 21 '24Sale7.816,70352,357449,092May 23 04:17 PM
Renz Justin AChief Financial OfficerMay 21 '24Sale7.815,16740,359300,546May 23 04:15 PM
RAAB MICHAELPresident & CEOMay 21 '24Sale7.8131,484245,9221,277,773May 23 04:13 PM
GRAMMER ELIZABETH ASee RemarksMay 21 '24Sale7.816,92754,107199,469May 23 04:10 PM
Felsch Robert OraSee RemarksMay 21 '24Sale7.813,48527,22195,127May 23 04:08 PM
Blanks RobertSee RemarksMay 21 '24Sale7.814,85537,922362,331May 23 04:07 PM
RAAB MICHAELPresident & CEOMay 14 '24Sale7.993,00023,9701,307,933May 15 06:15 PM
Felsch Robert OraSee RemarksMay 06 '24Option Exercise1.48119,101176,445303,935May 09 04:03 PM
Felsch Robert OraSee RemarksMay 06 '24Sale8.81207,9881,831,50395,947May 09 04:03 PM
GRAMMER ELIZABETH ASee RemarksMay 06 '24Option Exercise1.87219,937410,787487,930May 09 04:03 PM
GRAMMER ELIZABETH ASee RemarksMay 06 '24Sale8.88284,1702,522,217203,760May 09 04:03 PM
GRAMMER ELIZABETH ASee RemarksMay 03 '24Sale9.0045,000405,000267,993May 07 06:24 PM
Williams Laura AChief Medical OfficerMay 03 '24Option Exercise0.9930,00029,700410,138May 07 04:48 PM
Williams Laura AChief Medical OfficerMay 03 '24Sale8.3539,949333,574370,189May 07 04:48 PM
RAAB MICHAELPresident & CEOApr 29 '24Option Exercise0.9930,00029,7001,340,933May 01 07:59 PM
RAAB MICHAELPresident & CEOApr 29 '24Sale6.4030,000192,0571,310,933May 01 07:59 PM
RAAB MICHAELPresident & CEOApr 15 '24Sale7.067,50052,9241,310,933Apr 17 04:20 PM
RAAB MICHAELPresident & CEOApr 01 '24Sale7.311,51811,0971,318,433Apr 02 04:05 PM
GRAMMER ELIZABETH ASee RemarksMar 20 '24Sale7.7386,000664,978312,993Mar 22 04:42 PM
Rosenbaum David P.Chief Development OfficerFeb 26 '24Sale9.205,18347,684175,936Feb 28 06:57 PM
Rosenbaum David P.Chief Development OfficerFeb 20 '24Sale8.755,01743,880378,985Feb 22 06:30 PM
Rosenbaum David P.Chief Development OfficerFeb 20 '24Sale8.752,29420,064181,119Feb 22 06:30 PM
Renz Justin AChief Financial OfficerFeb 20 '24Sale8.755,34146,714304,835Feb 22 05:01 PM
RAAB MICHAELPresident & CEOFeb 20 '24Sale8.7522,917200,4391,319,951Feb 22 04:58 PM
Blanks RobertSee RemarksFeb 20 '24Sale8.755,01743,880368,186Feb 22 04:58 PM
GRAMMER ELIZABETH ASee RemarksFeb 20 '24Sale8.754,43238,764398,993Feb 22 04:57 PM
Rodriguez SusanChief Commercial OfficerFeb 20 '24Sale8.756,92860,594452,795Feb 22 04:56 PM
Felsch Robert OraSee RemarksFeb 20 '24Sale8.752,35220,571184,834Feb 22 04:56 PM
Williams Laura AChief Medical OfficerFeb 20 '24Sale8.754,80342,008380,138Feb 22 04:56 PM
Rosenbaum David P.Chief Development OfficerFeb 08 '24Sale9.1815,344140,846384,002Feb 09 04:14 PM
Rosenbaum David P.Chief Development OfficerJan 08 '24Sale6.6430,000199,200286,596Jan 10 05:36 PM
Renz Justin AChief Financial OfficerDec 26 '23Option Exercise0.9975,00074,250407,426Dec 28 05:44 PM
Renz Justin AChief Financial OfficerDec 26 '23Sale6.36225,0001,430,122182,426Dec 28 05:44 PM
Rosenbaum David P.Chief Development OfficerDec 18 '23Sale6.075,67534,447316,596Dec 20 04:49 PM
Rosenbaum David P.Chief Development OfficerDec 14 '23Sale5.557,00038,850322,271Dec 15 06:13 PM
GRAMMER ELIZABETH ASee RemarksDec 11 '23Sale5.0850,000253,925275,675Dec 13 05:44 PM
Rosenbaum David P.Chief Development OfficerDec 08 '23Sale5.2720,000105,476329,271Dec 08 05:58 PM
Rosenbaum David P.Chief Development OfficerDec 05 '23Sale5.0010,27251,360349,271Dec 06 04:49 PM
Rosenbaum David P.Chief Development OfficerNov 30 '23Sale4.503,00013,500359,543Dec 01 04:47 PM
Williams Laura AChief Medical OfficerNov 20 '23Sale4.362,58111,259266,191Nov 22 05:22 PM
Rosenbaum David P.Chief Development OfficerNov 20 '23Sale4.362,83512,367362,543Nov 22 05:21 PM
Rosenbaum David P.Chief Development OfficerNov 20 '23Sale4.369324,066113,293Nov 22 05:21 PM
Rodriguez SusanChief Commercial OfficerNov 20 '23Sale4.364,71420,563346,973Nov 22 05:20 PM
Renz Justin AChief Financial OfficerNov 20 '23Sale4.362,87312,533332,426Nov 22 05:20 PM
RAAB MICHAELPresident & CEONov 20 '23Sale4.3611,36849,589867,868Nov 22 05:19 PM
GRAMMER ELIZABETH ASee RemarksNov 20 '23Sale4.362,38410,399325,675Nov 22 05:19 PM
Felsch Robert OraSee RemarksNov 20 '23Sale4.361,0444,554117,066Nov 22 05:18 PM
Blanks RobertSee RemarksNov 20 '23Sale4.362,83512,367260,453Nov 22 05:17 PM
Williams Laura AChief Medical OfficerNov 15 '23Sale4.0025,00099,998266,839Nov 17 05:30 PM
Rosenbaum David P.Chief Development OfficerOct 10 '23Sale4.001,6446,576365,378Oct 12 05:09 PM